Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins

Cancer Science

Volumn 102, Issue 7, 2011, Pages 1388-1395

  Lee, Kyung Hun ^a   Lee, Ju Hee ^b,d   Han, Sae Won ^a,b   Im, Seock Ah ^a,b   Kim, Tae You ^a,b,c   Oh, Do Youn ^a,b   Bang, Yung Jue ^a,b,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90; OXALIPLATIN; PROTEASOME; PROTEIN INHIBITOR; PROTEIN KINASE B; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN TISSUE; IC 50; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; DRUG SYNERGISM; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; NEOPLASM PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, ERBB-2; RESORCINOLS; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE;

EID: 79959313696     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01944.x     Document Type: Article

References (35)

1. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72.
2. Bali P, George P, Cohen P et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 2004; 10: 4991-7.
3. Nimmanapalli R, Fuino L, Bali P et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003; 63: 5126-35.
4. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007; 13: 1625-9.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
6. Cervantes A, Rosello S, Roda D, Rodriguez-Braun E. The treatment of advanced gastric cancer: current strategies and future perspectives. Ann Oncol 2008; 19 (Suppl 5): v103-7.
7. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 2008; 43: 256-64.
8. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
9. Zuo DS, Dai J, Bo AH, Fan J, Xiao XY. Significance of expression of heat shock protein90alpha in human gastric cancer. World J Gastroenterol 2003; 9: 2616-8.
10. Giaginis C, Daskalopoulou SS, Vgenopoulou S, Sfiniadakis I, Kouraklis G, Theocharis SE. Heat Shock Protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival. BMC Gastroenterol 2009; 9: 14.
11. Lang SA, Klein D, Moser C et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 2007; 6: 1123-32.
12. Lee JH, Park JH, Jung Y et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 2006; 5: 3085-95.
13. Park JH, Kim SH, Choi MC et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 2008; 368: 318-22.
14. Park JH, Jong HS, Kim SG et al. Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med 2008; 86: 117-28.
15. Eccles SA, Massey A, Raynaud FI et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68: 2850-60.
16. Jensen MR, Schoepfer J, Radimerski T et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008; 10: R33.
17. Stuhmer T, Zollinger A, Siegmund D et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 2008; 22: 1604-12.
18. Ku JL, Park JG. Biology of SNU cell lines. Cancer Res Treat 2005; 37: 1-19.
19. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-24.
20. Park JH, Kim TY, Jong HS et al. Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. Clin Cancer Res 2003; 9: 433-40.
21. Stingl L, Stuhmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 2010; 102: 1578-91.
22. Kaiser M, Lamottke B, Mieth M et al. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur J Haematol 2010; 84: 337-44.
23. Gaspar N, Sharp SY, Eccles SA et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010; 9: 1219-33.
24. Kim SY, Kim HP, Kim YJ et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008; 32: 89-95.
25. Kim JW, Kim HP, Im SA et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008; 272: 296-306.
26. Ramanathan RK, Egorin MJ, Eiseman JL et al. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 2007; 13: 1769-74.
27. Oikonomopoulou K, Soosaipillai A, Diamandis EP. Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition. Clin Biochem 2009; 42: 1705-12.
28. Matei D, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB. The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J Biol Chem 2007; 282: 445-53.
29. Zhang L, Nephew KP, Gallagher PJ. Regulation of death-associated protein kinase. Stabilization by HSP90 heterocomplexes. J Biol Chem 2007; 282: 11795-804.
30. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003; 63: 2139-44.
31. García-Morales P, Carrasco-García E, Ruiz-Rico P et al. Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G2/M arrest in glioblastoma cell lines. Oncogene 2007; 26: 7185-93.
32. Welsh SJ, Titley J, Brunton L et al. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Cancer Res 2000; 6: 2538-46.
33. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000; 60: 3940-6.
34. Angus SP, Wheeler LJ, Ranmal SA et al. Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem 2002; 277: 44376-84.
35. Moser C, Lang SA, Kainz S et al. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther 2007; 6: 2868-78.